Qi Jing, Li Lanqian, Yan Xueqing, Hua Wenxi, Zhou Zixiong
Department of Biochemistry and Molecular Biology, The School of Basic Medical Sciences, Fujian Medical University, No. 1, Xuefu North Road, University Town, Fuzhou 350122, China.
Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.
Antioxidants (Basel). 2023 Sep 4;12(9):1718. doi: 10.3390/antiox12091718.
Liver fibrosis is a major challenge to global health because of its various complications, including cirrhosis and hepatocarcinoma, while no effective treatment is available for it. Sappanone A (SA) is a homoisoflavonoid extracted from the heartwood of Linn. with anti-inflammatory and antioxidant properties. However, the effects of SA on hepatic fibrosis remain unknown. This study aimed to investigate the protective effects of SA on carbon tetrachloride (CCl)-induced liver fibrosis in mice. To establish a liver fibrosis model, mice were treated intraperitoneally (i.p.) with CCl for 4 weeks. SA (25, 50, and 100 mg/kg body weight) was i.p. injected every other day during the same period. Our data indicated that SA decreased liver injury, fibrotic responses, and inflammation due to CCl exposure. Consistently, SA reduced oxidative stress and its-mediated hepatocyte death in fibrotic livers. Of note, SA could not directly affect the activation of hepatic stellate cells. Mechanistically, SA treatment lessened oxidative stress-triggered cell death in hepatocytes after CCl exposure. SA down-regulated the expression of M1 macrophage polarization markers (CD86 and iNOS) and up-regulated the expression of M2 macrophage polarization markers (CD163, IL-10, and Arg1) in livers and macrophages. Meanwhile, SA induced the activation of peroxisome proliferator-activated receptor gamma (PPARγ). However, decreased inflammatory responses and the trend of M2 macrophage polarization provided by SA were substantially abolished by SR202 (a PPARγ inhibitor) treatment in macrophages. Additionally, SA treatment promoted fibrosis regression. Taken together, our findings revealed that treatment with SA alleviated CCl-induced fibrotic liver in mice through suppression of oxidative stress-mediated hepatocyte death and promotion of M2 macrophage polarization via PPARγ. Thus, SA might pave the way for a new hepatoprotective agent to treat liver fibrosis.
肝纤维化因其各种并发症(包括肝硬化和肝癌)而成为全球健康面临的重大挑战,然而目前尚无有效的治疗方法。苏木酮A(SA)是从苏方木的心材中提取的一种高异黄酮,具有抗炎和抗氧化特性。然而,SA对肝纤维化的影响尚不清楚。本研究旨在探讨SA对四氯化碳(CCl)诱导的小鼠肝纤维化的保护作用。为建立肝纤维化模型,小鼠腹腔注射CCl 4周。在同一时期,每隔一天腹腔注射SA(25、50和100mg/kg体重)。我们的数据表明,SA减轻了CCl暴露引起的肝损伤、纤维化反应和炎症。同样,SA降低了纤维化肝脏中的氧化应激及其介导的肝细胞死亡。值得注意的是,SA不能直接影响肝星状细胞的激活。从机制上讲,SA处理减轻了CCl暴露后氧化应激引发的肝细胞死亡。SA下调了肝脏和巨噬细胞中M1巨噬细胞极化标志物(CD86和iNOS)的表达,并上调了M2巨噬细胞极化标志物(CD163、IL-10和Arg1)的表达。同时,SA诱导了过氧化物酶体增殖物激活受体γ(PPARγ)的激活。然而,SR202(一种PPARγ抑制剂)处理巨噬细胞后,SA提供的炎症反应降低和M2巨噬细胞极化趋势基本消失。此外,SA治疗促进了纤维化的消退。综上所述,我们的研究结果表明,SA治疗通过抑制氧化应激介导的肝细胞死亡和通过PPARγ促进M2巨噬细胞极化,减轻了CCl诱导的小鼠肝纤维化。因此,SA可能为治疗肝纤维化的新型肝保护剂开辟道路。